{"id":"recombinant-hepatitis-b-virus-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site pain"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2109163","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By introducing a recombinant form of the hepatitis B virus surface antigen, the vaccine triggers the body's immune system to produce antibodies against the virus, providing protection against infection.","oneSentence":"This vaccine stimulates an immune response against the hepatitis B virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:29.339Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of hepatitis B infection"}]},"trialDetails":[{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":240},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT02750202","phase":"PHASE3","title":"Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2018-07-01","conditions":"Genital Warts","enrollment":52},{"nctId":"NCT07147400","phase":"PHASE2","title":"Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults","status":"RECRUITING","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2025-08-22","conditions":"Prevention of Malaria Transmission and Clinical Malaria","enrollment":1200},{"nctId":"NCT03910972","phase":"PHASE1, PHASE2","title":"Sm-TSP-2 Schistosomiasis Vaccine in Healthy Ugandan Adults","status":"COMPLETED","sponsor":"Baylor College of Medicine","startDate":"2019-10-07","conditions":"Schistosomiasis, Schistosoma Mansoni","enrollment":290},{"nctId":"NCT04843852","phase":"PHASE1","title":"TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B","status":"RECRUITING","sponsor":"University of Maryland, Baltimore","startDate":"2025-10-16","conditions":"Hepatitis B, Chronic Hepatitis B","enrollment":10},{"nctId":"NCT00988767","phase":"PHASE1","title":"Safety and Immunogenicity of a Naked DNA-based Vaccine Therapy in Patients With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2001-02","conditions":"Chronic Hepatitis B","enrollment":10},{"nctId":"NCT03038802","phase":"PHASE1, PHASE2","title":"A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection","status":"NOT_YET_RECRUITING","sponsor":"Vaxine Pty Ltd","startDate":"2026-03-01","conditions":"Chronic Hepatitis b","enrollment":40},{"nctId":"NCT06038617","phase":"PHASE4","title":"Safety of Simultaneous mRNA COVID-19 Vaccine With Other Childhood Vaccines in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2023-10-30","conditions":"Fever After Vaccination, Fever, Seizures Fever","enrollment":344},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT00505063","phase":"PHASE2","title":"Prospective Trial of Vaccine Responses in Childhood Cancer Survivors","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-07-10","conditions":"Childhood Cancer, Multiple Diseases","enrollment":76},{"nctId":"NCT05482295","phase":"PHASE3","title":"Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III)","status":"NOT_YET_RECRUITING","sponsor":"PT Bio Farma","startDate":"2025-09","conditions":"Vaccine Reaction, Vaccine Adverse Reaction","enrollment":540},{"nctId":"NCT05482282","phase":"PHASE3","title":"Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma)","status":"WITHDRAWN","sponsor":"PT Bio Farma","startDate":"2025-12","conditions":"Diphtheria Vaccine Adverse Reaction, Tetanus Vaccine Adverse Reaction, Pertussis Vaccine Adverse Reaction","enrollment":""},{"nctId":"NCT04970836","phase":"NA","title":"The Immune Responses After Hepatitis B Revaccination Doses in a Young Cohort","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2021-08-01","conditions":"Hepatitis B, Vaccination; Infection, Preventable Disease, Vaccine","enrollment":240},{"nctId":"NCT05272735","phase":"PHASE4","title":"HBV Vaccination of Healthy Volunteers to Evaluate the Composition of Germinal Centers","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2022-12-10","conditions":"Hepatitis B","enrollment":12},{"nctId":"NCT06162299","phase":"PHASE1","title":"A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002","status":"TERMINATED","sponsor":"Yisheng Biopharma (Singapore) Pte. Ltd.","startDate":"2024-07-01","conditions":"Chronic Hepatitis B","enrollment":16},{"nctId":"NCT06800131","phase":"PHASE1","title":"Hepatitis B Vaccine Delivered Trans-dermally by MAP","status":"NOT_YET_RECRUITING","sponsor":"International Vaccine Institute","startDate":"2025-02-05","conditions":"Hepatitis B Vaccine","enrollment":40},{"nctId":"NCT02942277","phase":"PHASE1","title":"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-10-21","conditions":"Malaria","enrollment":301},{"nctId":"NCT03934736","phase":"PHASE1","title":"HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2019-04-22","conditions":"End Stage Renal Disease on Hemodialysis (Diagnosis)","enrollment":119},{"nctId":"NCT06515938","phase":"NA","title":"Study on New Strategies for Hepatitis B Virus Immunization","status":"COMPLETED","sponsor":"Wu Jiang","startDate":"2013-01-01","conditions":"Vaccine Reaction","enrollment":1169},{"nctId":"NCT04456504","phase":"PHASE4","title":"HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"2020-09-15","conditions":"Healthcare Worker, Hepatitis B Vaccine, Nonresponder","enrollment":49},{"nctId":"NCT06209398","phase":"PHASE4","title":"Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine","status":"UNKNOWN","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2018-05-24","conditions":"Hand, Foot and Mouth Disease","enrollment":510},{"nctId":"NCT03149874","phase":"NA","title":"Accelerated Vaccination Schedule Against Hepatitis B Virus With Combined Hepatitis A and B Vaccine Among Hemodialysis Patients","status":"COMPLETED","sponsor":"Benha University","startDate":"2014-12-01","conditions":"Hepatitis B, Hemodialysis Complication","enrollment":114},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT03919578","phase":"PHASE2, PHASE3","title":"Protectivity and Safety Following Recombinant Hepatitis B Vaccine","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2019-09-11","conditions":"Immunogenicity","enrollment":536},{"nctId":"NCT04723602","phase":"PHASE1","title":"Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults","status":"COMPLETED","sponsor":"Albert B. Sabin Vaccine Institute","startDate":"2021-01-06","conditions":"Ebola Virus Disease, Marburg Virus Disease","enrollment":32},{"nctId":"NCT04188223","phase":"PHASE1","title":"Safety and Immunogenicity Following Recombinant Hepatitis B (Bio Farma) Vaccine in Adults & Children","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2019-12-03","conditions":"Hepatitis B","enrollment":100},{"nctId":"NCT04531098","phase":"PHASE3","title":"A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2006-03-02","conditions":"Hepatitis B","enrollment":402},{"nctId":"NCT04209400","phase":"PHASE3","title":"Safety and Immunogenicity of Recombinant Hepatitis B Vaccine Sci-B-Vac® Compared to Engerix-B®","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2014-04-18","conditions":"Hepatitis B","enrollment":100},{"nctId":"NCT05451420","phase":"NA","title":"Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy","status":"COMPLETED","sponsor":"Henan Provincial People's Hospital","startDate":"2017-12-01","conditions":"Chronic Hepatitis B","enrollment":33},{"nctId":"NCT04179786","phase":"PHASE4","title":"A Study to Qualify an In-house Reference Standard Batch of Sci-B-Vac™","status":"COMPLETED","sponsor":"VBI Vaccines Inc.","startDate":"2015-11-01","conditions":"Hepatitis B","enrollment":91},{"nctId":"NCT03316807","phase":"PHASE4","title":"Immunogenicity of Hepatitis B Vaccination in HIV-infected Adults","status":"COMPLETED","sponsor":"Suping Wang","startDate":"2014-10","conditions":"Hepatitis B Vaccine","enrollment":182},{"nctId":"NCT02959775","phase":"PHASE4","title":"Immunogenicity of Hepatitis B Vaccination Among Drug Users","status":"COMPLETED","sponsor":"Shanxi Medical University","startDate":"2014-08","conditions":"Hepatitis B Vaccination","enrollment":480},{"nctId":"NCT02963714","phase":"PHASE4","title":"Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients","status":"COMPLETED","sponsor":"Suping Wang","startDate":"2014-12","conditions":"Hepatitis B Vaccine","enrollment":352},{"nctId":"NCT03627507","phase":"PHASE2, PHASE3","title":"Non Inferiority Trial of Locally Manufactured 'Hepa-B' Vaccine in Bangladesh.","status":"COMPLETED","sponsor":"International Centre for Diarrhoeal Disease Research, Bangladesh","startDate":"2018-07-29","conditions":"Hepatitis B Infection","enrollment":158},{"nctId":"NCT03685708","phase":"PHASE2","title":"HEPLISAV-B Hepatitis B Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's-Tyrosine Kinase Inhibitor (BTK-I)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2018-12-07","conditions":"Hepatitis, Safety and Tolerability","enrollment":78},{"nctId":"NCT04071379","phase":"PHASE3","title":"Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B","status":"COMPLETED","sponsor":"PT Bio Farma","startDate":"2020-10-13","conditions":"Immunogenicity, Safety","enrollment":220},{"nctId":"NCT02991599","phase":"PHASE4","title":"Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients","status":"COMPLETED","sponsor":"Shanxi Medical University","startDate":"2014-10","conditions":"Hepatitis B Vaccine","enrollment":196},{"nctId":"NCT05099757","phase":"PHASE4","title":"The Immunogenicity and Persistence of Booster Dose With Hepatitis B Vaccine in College Students","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2022-02-20","conditions":"Hepatitis B Vaccine","enrollment":150},{"nctId":"NCT00000745","phase":"PHASE1","title":"A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":72},{"nctId":"NCT00000633","phase":"PHASE1","title":"A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Immuno-AG Recombinant HIV gp160 in Asymptomatic HIV Seropositive Individuals","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":55},{"nctId":"NCT00013871","phase":"NA","title":"Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections, Hepatitis B, Measles","enrollment":300},{"nctId":"NCT00000943","phase":"NA","title":"A Study to Test If Giving Remune (an HIV Vaccine) Can Improve the Immune Systems of HIV-Positive Patients Who Are Also Participating in ACTG 328","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"HIV Infections","enrollment":50},{"nctId":"NCT04075201","phase":"PHASE1","title":"Clinical Trial of Recombinant Hepatitis B Vaccine (Hansenula Polymorpha, 10μg)","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-07","conditions":"Hepatitis B","enrollment":144},{"nctId":"NCT03274102","phase":"PHASE4","title":"Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With EPI Vaccines","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2017-04-22","conditions":"Hand, Foot and Mouth Disease","enrollment":780},{"nctId":"NCT00985426","phase":"PHASE3","title":"Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2009-09","conditions":"Chronic Kidney Disease","enrollment":521},{"nctId":"NCT04870021","phase":"PHASE4","title":"Hepatitis B Birth Dose for Newborns","status":"COMPLETED","sponsor":"Quaid-e-Azam University","startDate":"2015-03-15","conditions":"Hepatitis B, Immunization; Infection","enrollment":218},{"nctId":"NCT03110757","phase":"PHASE1","title":"A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-20","conditions":"Schistosomiasis","enrollment":60},{"nctId":"NCT03207750","phase":"PHASE3","title":"This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-09-14","conditions":"Rotavirus Infection, Rotavirus Vaccines","enrollment":1280},{"nctId":"NCT01014845","phase":"PHASE3","title":"Clinical Trial of Recombinant Hepatitis E Vaccine","status":"COMPLETED","sponsor":"Xiamen University","startDate":"2007-08","conditions":"Hepatitis E","enrollment":112604},{"nctId":"NCT04326803","phase":"PHASE4","title":"Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response","status":"UNKNOWN","sponsor":"Pontificia Universidad Catolica de Chile","startDate":"2020-06-01","conditions":"Hepatitis B","enrollment":200},{"nctId":"NCT03056924","phase":"","title":"Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2017-07-05","conditions":"Inflammatory Bowel Diseases","enrollment":173},{"nctId":"NCT04162223","phase":"EARLY_PHASE1","title":"Hepatitis B Vaccine in Seniors","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2000-03-29","conditions":"Hepatitis B Vaccination","enrollment":52},{"nctId":"NCT02621112","phase":"PHASE2, PHASE3","title":"HBV Vaccine in Renal Failure Patients","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2016-01","conditions":"Renal Failure","enrollment":94},{"nctId":"NCT02203357","phase":"PHASE4","title":"A Randomized,Parallel-group Clinical Trial of Hepatitis B Vaccine With Different Dosages and Schedules in Healthy Adults","status":"COMPLETED","sponsor":"Peking University","startDate":"2014-03","conditions":"Hepatitis B","enrollment":353},{"nctId":"NCT04056728","phase":"PHASE4","title":"A Phase IV Study to Assess the Safety of EupentaTM Inj","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-09-23","conditions":"Hepatitis B, Diphtheria, Haemophilus Influenzae Type B Infection","enrollment":3000},{"nctId":"NCT02964910","phase":"PHASE4","title":"A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(the Chronic Hepatitis B Patients )","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2016-08","conditions":"Hepatitis E","enrollment":475},{"nctId":"NCT03962803","phase":"PHASE4","title":"Immunogenicity and Persistence of Hepatitis B Vaccination in HIV-Infected Patients","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2019-06-05","conditions":"Hepatitis B Vaccine","enrollment":300},{"nctId":"NCT03962816","phase":"PHASE4","title":"Immunogenicity and Persistence of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2019-05-26","conditions":"Hepatitis B Vaccine","enrollment":300},{"nctId":"NCT03962881","phase":"PHASE4","title":"Research on Optimal Immunization Strategy of Hepatitis B Vaccine in Chronic Kidney Disease Population","status":"UNKNOWN","sponsor":"Shanxi Medical University","startDate":"2019-05-25","conditions":"Hepatitis B Vaccine","enrollment":300},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01553279","phase":"PHASE3","title":"Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2012-03-30","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":284},{"nctId":"NCT02169674","phase":"PHASE4","title":"Hepatitis B Booster Study in Adolescence","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Hepatitis B","enrollment":359},{"nctId":"NCT02117934","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2014-04","conditions":"Healthy","enrollment":8374},{"nctId":"NCT01282762","phase":"","title":"Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"Chronic Kidney Disease","enrollment":147},{"nctId":"NCT00435812","phase":"PHASE3","title":"Safety and Efficacy of HEPLISAV™ Hepatitis B Virus Vaccine Compared With Engerix-B® Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-12","conditions":"Hepatitis B","enrollment":2428},{"nctId":"NCT01195246","phase":"PHASE3","title":"Safety and Immunogenicity of HEPLISAV™ a Hepatitis B Virus Vaccine in Adults on Hemodialysis","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-12","conditions":"End Stage Renal Disease","enrollment":155},{"nctId":"NCT01005407","phase":"PHASE3","title":"Safety and Immunogenicity Study of the Hepatitis B Virus (HBV) Vaccine, HEPLISAV Compared to Engerix-B Vaccine","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2010-02","conditions":"Healthy","enrollment":2452},{"nctId":"NCT00426712","phase":"PHASE1","title":"Safety of HEPLISAV™ Hepatitis B Virus Vaccine in End-stage Kidney Failure Patients","status":"COMPLETED","sponsor":"Dynavax Technologies Corporation","startDate":"2006-01","conditions":"Hepatitis B","enrollment":42},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT03619590","phase":"","title":"Twinrix Pregnancy Registry","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-05-18","conditions":"Hepatitis","enrollment":245},{"nctId":"NCT02003703","phase":"PHASE3","title":"Comparative Efficacy of an Intensified Re-vaccination Scheme for Hepatitis B Virus Infection Among Patients Infected With HIV .","status":"COMPLETED","sponsor":"Universidad de Valparaiso","startDate":"2015-05","conditions":"Hepatitis B, HIV","enrollment":107},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT02055365","phase":"NA","title":"Pilot Study: Gene Expression Profiling of Immune Response to HBV Vaccination in Healthy Volunteers","status":"COMPLETED","sponsor":"Rockefeller University","startDate":"2014-02-18","conditions":"Hepatitis B","enrollment":10},{"nctId":"NCT00432042","phase":"PHASE3","title":"Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-01-12","conditions":"Varicella, Measles, Mumps","enrollment":955},{"nctId":"NCT00873652","phase":"","title":"Observational Study of Immune Response to Hepatitis B Childhood Booster","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2009-02","conditions":"Healthy","enrollment":28},{"nctId":"NCT02584543","phase":"PHASE4","title":"A Phase Ⅳ Clinical Trial of the Recombinant Hepatitis E Vaccine (Escherichia Coli)(Coadministration With Recombinant Hepatitis B Vaccine)","status":"COMPLETED","sponsor":"Xiamen Innovax Biotech Co., Ltd","startDate":"2015-10","conditions":"Hepatitis E, Hepatitis B","enrollment":602},{"nctId":"NCT00657709","phase":"PHASE3","title":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Serogroup B Meningococcal Meningitis","enrollment":3630},{"nctId":"NCT03219203","phase":"PHASE4","title":"Immunologic Response of Hepatitis B Vaccine","status":"UNKNOWN","sponsor":"Chiang Mai University","startDate":"2017-07-01","conditions":"Hepatitis B","enrollment":80},{"nctId":"NCT03193775","phase":"NA","title":"Impact of Hepatitis B Vaccination on HBs Antigenemia","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2011-08-01","conditions":"HBV","enrollment":220},{"nctId":"NCT02797782","phase":"","title":"Study of the Long Term Efficacy of Recombinant Hepatitis B Vaccine in Nile Delta of Egypt","status":"UNKNOWN","sponsor":"Sherief Abd-Elsalam","startDate":"2016-06","conditions":"Hepatitis B Vaccines","enrollment":200},{"nctId":"NCT01453348","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of Combined Hepatitis A/B Vaccine With MenACWY-CRM Conjugate Vaccine","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-10","conditions":"Meningococcal Disease, Meningococcal Meningitis, Hepatitis A","enrollment":252},{"nctId":"NCT00414050","phase":"PHASE3","title":"A Study of 2 Doses of a Hepatitis B Vaccine (V232 RECOMBIVAX HB) in Healthy Infants (V232-057)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-06","conditions":"Hepatitis B","enrollment":1718},{"nctId":"NCT02713620","phase":"PHASE4","title":"Hepatitis B Vaccination in HIV-infected Adults","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2015-01","conditions":"Hepatitis B","enrollment":154},{"nctId":"NCT02732054","phase":"PHASE4","title":"Hepatitis B Vaccination in HIV-infected Adults With Low CD4 Cell Counts","status":"COMPLETED","sponsor":"Chiang Mai University","startDate":"2015-03","conditions":"Hepatitis B","enrollment":16},{"nctId":"NCT00440297","phase":"PHASE3","title":"Hepatitis B Vaccine Predialysis/Dialysis Study (V232-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-12","conditions":"Hepatitis B Virus Infection","enrollment":277},{"nctId":"NCT00440531","phase":"PHASE3","title":"Study of Recombinant Modified Process Hepatitis B Vaccine in Older Adults (V232-059)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-11","conditions":"Hepatitis B","enrollment":540},{"nctId":"NCT00517309","phase":"PHASE3","title":"Study to Test the Safety of HPV Vaccine in Women (V501-011)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-12-28","conditions":"Cervical Cancer, Genital Warts","enrollment":1877},{"nctId":"NCT00322361","phase":"PHASE2","title":"Modified Process Hepatitis B Vaccine in Healthy Neonates (V232-056)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-05","conditions":"Hepatitis B, Hepatocellular Carcinoma","enrollment":566},{"nctId":"NCT00489099","phase":"PHASE3","title":"A Research Study to Test Safety, Tolerability, and Immunogenicity of a Recombinant Hepatitis B Vaccine Manufactured With an Upgrade to the Production Process (V232-054)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-06","conditions":"Hepatitis B Infection","enrollment":860},{"nctId":"NCT00697866","phase":"PHASE3","title":"Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-08","conditions":"Hepatitis B","enrollment":951},{"nctId":"NCT00697749","phase":"PHASE3","title":"Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-04","conditions":"Hepatitis B","enrollment":230},{"nctId":"NCT02898922","phase":"PHASE4","title":"Robust Antibody and Cytokine Response to Hepatitis B Vaccine Among Not-in-treatment Patients With Chronic Hepatitis C：An Open-label Control Study in China","status":"COMPLETED","sponsor":"Shandong Province Centers for Disease Control and Prevention","startDate":"2013-06","conditions":"Hepatitis B Vaccines","enrollment":300},{"nctId":"NCT00120796","phase":"PHASE3","title":"Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)","status":"TERMINATED","sponsor":"French National Agency for Research on AIDS and Viral Hepatitis","startDate":"2005-08","conditions":"Hepatitis B","enrollment":8},{"nctId":"NCT01339000","phase":"PHASE2","title":"Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04","conditions":"Breast Cancer, Colon Cancer, Bladder Cancer","enrollment":1},{"nctId":"NCT00654901","phase":"PHASE3","title":"Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2008-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":881},{"nctId":"NCT02764671","phase":"PHASE4","title":"Safety and Immunogenicity of Recombinant Hepatitis B Vaccines in the Neonates","status":"UNKNOWN","sponsor":"Shenzhen Kangtai Biological Products Co., LTD","startDate":"2015-05","conditions":"Hepatitis, Hepatitis B, Liver Diseases","enrollment":5000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":19,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Engerix B (GlaxoSmithKline)"],"phase":"phase_3","status":"active","brandName":"Recombinant Hepatitis B Virus Vaccine","genericName":"Recombinant Hepatitis B Virus Vaccine","companyName":"Universidad de Valparaiso","companyId":"universidad-de-valparaiso","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates an immune response against the hepatitis B virus. Used for Prevention of hepatitis B infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}